Business
Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium
About this update from Passage Bio, Inc.
[{"type":"text","content":"Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium presentations on clinical trial designs for Imagine-1 and GALax-C, the clinical trial for Krabbe disease, Wednesday, February 9Global Genes poster presentation on Passage Bio-supported patient identification and engagement initiative for rare central nervous system disorders, Tuesday, February 8Management to host conference call and webcast following late-breaker GM1 gangliosidosis presentation on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced its participation at the 18th Annual WORLDSymposium, a research conference dedicated to lysosomal diseases, taking place virtually and in person in San Diego, Calif., February 7 – 11, 2022. Passage Bio is a lead sponsor of the patient advocacy organization Global Genes’ patient identification and engagement initiative for rare CNS disorders, which will be featured in a poster presentation on Tuesday, February 8. Passage Bio will also deliver two platform presentations on the designs of its clinical trials for Imagine-1 for GM1 gangliosidosis and GALax-C for Krabbe disease on Wednesday, February 9. On Friday, February 11, as part of the conference’s late-breaking science session, the company will present safety and clinical development milestone data for the two patients in Cohort 1 of the Imagine-1 clinical trial. “As part of our Imagine-1 late-breaker presentation, we will be excited to share new clinical data from Cohort 1 in the ongoing Imagine-1 trial,” said Bruce Goldsmith, Ph.D., president and chief executive officer, Passage Bio. “We are also looking forward to attending WORLD to learn about new scientific research and engage with other researchers, physicians and patient advocacy groups, who share our commitment to continuing to advance the field with the development of transformative medicines for patients with rare CNS disorders.” Poster Presentation Tuesday, February 8, 3 to 5 p.m., Pacific Time, Translational Research Poster 191, Improving patient identification, inclusion and engagement in research for LDs and othe...